Objective. To study the usefulness of moclobemide and amitriptyline in the treatment of fibromyalgia (FM ) in females without psychiatric disorder.
F ( FM ) is a chronic pain syndrome charlevels [16 ] have been reported in patients suffering from FM in comparison to healthy controls or patients acterized by musculoskeletal pain, non-restorative sleep and fatigue, psychosomatic, psychiatric, neurological with other musculoskeletal disorders. The observation that plasma levels, as well as the transport ratio of and a variety of protean symptoms. Further, the symptoms are aggravated by external and/or internal plasma tryptophan, are decreased in comparison to healthy subjects [17] is consistent with the hypothesis stress [1, 2] . Although the pathogenesis of FM is poorly understood and the symptoms appear to arise that FM also belongs to the syndromes with a serotonin deficit in the brain. Further, in comparison to healthy from diverse causes, the cornerstone of clinical diagnosis is the presence of multiple palpable tender points subjects, in addition to those of serotonin, decreased levels of metabolites of noradrenaline and dopamine [3] , which also appear to reflect the general distress of an individual [4, 5] .
[18] have been reported in cerebrospinal fluid of FM patients, suggesting that a seminal defect in FM occurs In epidemiological surveys, the respective prevalences of FM in the North American general populaat a neuroregulatory level. Randomized, controlled clinical trials have demontion and in females aged 20-49 yr in Southern Norway have been reported to be 2% [6 ] and 10.5% [7] . Most strated that low doses of tri-and tetracyclic antidepressants, especially amitriptyline (AMI ), are more of the patients are females and the prevalence increases with aging [6 ] , since recoveries are exceptional [8, 9] . effective than placebo in the treatment of FM [19] [20] [21] [22] [23] .
On the other hand, other antidepressive agents, such Despite increasing research efforts, considerable debate remains concerning the role of peripheral and as the selective serotonin reuptake inhibitors fluoxetine [24] and citalopram [25] , in doses effective in the central factors in the aetiopathogenesis of FM. Although muscular pain is an integral feature of the treatment of depression, impose only an effect comparable to placebo on FM. Goldenberg and co-workers FM syndrome, controlled studies have failed to support a convincing role for muscle in the pathophysiology [26 ] , however, recently reported that AMI and fluoxetine may have an additive beneficial effect on fibroof the condition [10] . On behalf of central factors, significantly lower regional cerebral blood flow in myalgic symptoms. Moclobemide (MOCLO) is the first of a new class thalamus and caudate nuclei [11] , neurohormonal disturbances including low levels of insulin-like growth of reversible inhibitors of monoamine oxidase (MAO) A, the enzyme responsible for the breakdown of neurofactor 1 (somatomedin C ) [12, 13] , hypothalamicpituitary-adrenal axis hypofunction [14, 15] , decreased genic amines in the synaptic cleft and on the postsynaptic membrane. MOCLO inhibits the deamination of plasma neuropeptide Y [15] and increased prolactin serotonin, noradrenaline and dopamine, but does not affect monoamine uptake or release [27] . It is an whether MOCLO will produce a significantly higher placebo capsule 2 h before bedtime; (2) one MOCLO placebo capsule in the morning and afternoon, and number of responders than placebo in FM patients free from major psychiatric disorders. Secondarily, we one AMI capsule 2 h before bedtime; (3) one placebo capsule in the morning, afternoon and 2 h before wanted to see the adverse event profile of MOCLO in comparison to placebo and AMI in these patients.
bedtime. The study treatment was recommended to be taken Since the effect of MOCLO has never been studied before in the treatment of patients with FM, AMI and after meals. Only paracetamol tablets (500 mg) supplied by the sponsor (up to 4 g/day) were allowed as placebo were chosen as comparator arms. Our results may also be of interest for the pathogenetic understandescape medication from the screening visit onward. The patients registered their drug consumption in a ing of FM.
diary. Check-up visits with assessments were performed PATIENTS AND METHODS at baseline, and at 2, 6 and 12 weeks. If the patient tolerated the treatment, the dose was increased at the Patients The patients were recruited from our out-patient 2 week check-up to the target dose (450 mg MOCLO and 25 mg AMI ). Further, if the response was still clinics or were invited to participate by a letter from the register of FM patients. All the patients who unsatisfactory at the 6 week visit, the MOCLO and AMI doses could be increased to 600 and 37.5 mg, accepted the invitation were screened. Only female patients aged 18-65 yr and fulfilling the ACR 1990 respectively, with a concomitant increase in the number of placebo capsules. criteria [3] for FM at screening and baseline visits were enrolled. Further, to be included, the patients
The patients were provided with the study drugs at each check-up visit, when they also returned unused had to score at baseline a minimum of 4 (moderate) on at least three of the four self-administered visual medication and empty containers for counting. analogue scales ( VAS ) (from 0 = not at all to 10 = very much). The items were: (1) patient's global Assessments At each check-up, the physician recorded his/her assessment of general health (GH ) ('How much has FM disabled your life during the recent week?'; (2) clinical impression of the change (CIC ) of FM (on a seven-point scale: 3 = very much improved, 0 = no pain ('How much pain have you had due to FM during the recent week?'); (3) sleep quality and quantity ('How change, −3 = very much worse). The patients assessed 1, 2 or 3 were judged as responders. much have sleeping problems disturbed your life during the recent week?'); (4) fatigue ('How tired have you
The patients recorded their GH, sleep quality and quantity, pain, and fatigue on self-administered 10 cm been during the recent week?').
People were excluded if they suffered from severe VAS. Patients' self-administered Sheehan's functional scales (0 = not at all; 10 = very much) (1) in work cardiovascular, pulmonary, hepatic, haematological or renal disease, glaucoma, were pregnant or lactating, or ('How much has your working capacity decreased due to your problems at present?'), (2) in social life and were not willing to discontinue all medication acting on the central nervous system, non-steroidal antifree time activities ('How much have your social life and free time activities decreased due to your problems inflammatory drugs and analgesics (other than paracetamol ). The tests for thyroid function, serum calcium and at present?') and (3) in the duties of family life ('How much do your family life and duties at home suffer creatine kinase also had to lie within reference values.
To exclude the patients with major depression, from your problems at present?') were recorded at each visit. In addition, adverse events, concurrent psychosis, obsessive-compulsive disorder or probable psychoactive drug use disorder, including excessive illnesses and drug consumption were also recorded. Further, at the baseline and 12 week visits, or if the alcohol consumption, at present or during the preceding 6 months, a clinical structured interview (Scid-Ro) patient discontinued in the trial, the number of ACR 1990 FM tender points (out of 18) [3] , the quality of [32] was conducted by a psychiatrist before inclusion. life in six dimensions by the patient self-administered
Nottingham Health Profile (NHP) [33] questionnaire Procedure and medication
The 12 week, double-blinded, parallel group, threeand the attending physician's clinical impression of the severity of FM (CIS) (from 1 = normal to 7 = one arm study was conducted in four centres. The randomization was organized centrally with sequentially among the most severely ill patients) were recorded. Because of the possible diurnal rhythm of symptoms, numbered envelopes consisting of blocks of six. Each MOCLO and AMI capsule contained 150 and 12.5 mg the visits were scheduled to take place at the same time of day. In self-administered scales, the values in the of active drug, respectively. The placebo capsules were identical to the active drugs.
mornings were recorded. At the screening visit, each patient received placebo capsules and paracetamol escape medication. After the
End points
The proportion of responders as assessed by the 2 week, single-blinded, placebo run-in period (at baseline), the eligible patients were assigned in a relationphysician was used as the primary efficacy end point.
Responders were the patients scoring 3 (very much ship of 1:1:1 to one of the following three regimens: (1) one MOCLO capsule in the morning (before 10 improved ), 2 (much improved) or 1 (minimally improved ) on the CIC scale at the treatment end point. a.m.) and afternoon (before 2 p.m.), and one AMI Likewise, the mean improvements of the patients on ( Fig. 1) . Two of them were withdrawn due to entry the CIC scale in each treatment arm were calculated.
violation, but since all patients received study medicaAs the secondary end points, the study protocol tion, they are also included in the analyses. Ninetydetermined the changes (1) on the 10 cm VAS: (i) GH, two patients completed the study according to the (ii) pain, (iii) sleep quality and quantity, (iv) fatigue protocol. The rates and reasons for withdrawals are and (v) on the three Sheehan's disability scales; (2) on shown in Fig. 1 . Although the overall discontinuation the six areas of the NHP scales; (3) in the number of rate was lowest in the AMI group, the differences in ACR 1990 FM tender points; and (4) in CIS.
overall rates or reasons for withdrawals between the In addition to spontaneous reporting, the patients treatment groups were statistically not significant. were asked about side-effects/adverse events at each visit. The physician's clinical global impression (CGI )
Patient demographics and clinical characteristics at of tolerability (from 1 = very poor to 4 = very good) baseline was used as the measure of the overall tolerability of Patient demographics did not differ between the the test drug.
treatment groups ( Table I ) . Neither did the psychiatric profiles nor the general health of the patients in the Statistical analysis three treatment arms differ statistically significantly at A sample size of 38 patients per active treatment screening or baseline visits (data not shown). Fourteen, group and placebo group was calculated to be required 16 and 16 patients in the MOCLO, AMI and placebo to obtain a 5% significance level and 80% power. When groups, respectively, had earlier been treated with anticipating a drop-out rate of 15%, 44 patients were antidepressants. calculated to be randomized in each treatment arm to
No statistically significant differences between the ensure an adequate group size. study treatment groups existed either in the number of The baseline demographic measurements were comtender points, CIS, the dimensions of NHP or the pared using ANOVA. All variables considered interval scaled were tested for homoscedasticity considering the two treatment groups. If heteroscedastic, a two-sample t-test with unequal variances was applied and P values were adjusted using Bonferroni correction. The distribution of the variables was tested using D'Agostino's test. If the variable did not have a normal distribution, Mann-Whitney's U-test was applied.
The null hypothesis in testing was that the three treatments had an equivalent response rate. Testing was started with overall comparison where all treatment groups were included. With interval-scaled variables, analysis of variance with equal replications and with the factors study drug group and treatment effect (RANOVA) was used. With ordinal-scaled variables, Kruskall-Wallis one-way analysis of variance was applied. In the case of statistical significance in any factor, or in their interaction, pairwise analyses were carried out. With an ordinal-scaled variable, the Mann-Whitney U-test was applied.
For discrete data, an extended x2 test for three independent samples was used in overall analysis.
The treatment responses (proportions) were com-F. 1.-Study schedule and the number of patients and exclusions, pared using Fisher's exact test.
as well as the schedule and reasons for discontinuations during
All tests were two-sided and the intention-to-treat the trial.
principle was applied. Difference was deemed to be statistically significant if the two-sided P value was Withdrawal from the study A total of 184 patients were screened to participate MOCLO, moclobemide; AMI, amitriptyline; BMI, body mass index.
in the trial and 130 patients were included in the study areas of Sheehan's functional scales, or in the symptomatic VAS at baseline ( Tables II and III ) .
Clinical improvement
Seventy-four per cent of the patients in the AMI arm responded beneficially to the therapy, while the respective figures in the MOCLO and placebo arms were 54 and 49%. The differences of AMI vs MOCLO and AMI vs placebo were statistically significant (0.044 and 0.017, respectively), while the difference between the MOCLO and placebo arms did not reach statistical significance.
The (Fig. 2) . A statistically significant improvement took place in all treatment groups (RANOVA), but in pairwise comparisons the difference in CIC was statistically significant in favour of AMI; between AMI The beneficial effect of AMI was already discernible and placebo; **P < 0.01 between AMI and placebo; +P < 0.05 at 2 weeks (Fig. 2) .
between AMI and MOCLO.
The physician's clinical impression of the severity (CIS) of FM and the number of tender points decreased during the study in all treatment groups In within-group comparisons: *P < 0.05; **P < 0.01; ***P < 0.001. MOCLO, moclobemide; AMI, amitriptyline. In within-group comparisons: *P < 0.05; **P < 0.01; ***P < 0.001.
highly statistically significantly (P < 0.001), but the collapse. She had had similar attacks earlier, but the causal relationship was judged to be possible and the differences between the treatment arms did not reach statistical significance ( Table II ) Tables II and III. According to overall RANOVA, a statistically highly Compliance (the difference between the capsules the patients should have taken and those returned ) with significant improvement occurred in GH perception, pain, quality and quantity of sleep, and fatigue the study protocol was excellent: 98, 97 and 97% in the MOCLO, AMI and placebo groups, respectively. ( Table II ) . At the end, the sleep index of the AMI group was statistically significantly lower than that of On the other hand, the mean daily consumption of paracetamol was statistically significantly greater in the other treatment groups (P < 0.01). In within-group comparisons, statistically significant improvements the placebo group than in the two other groups (P = 0.012). The average (..) number of 500 mg took place in all VAS of the patients in the AMI arm, while the improvements in the GH and pain, or GH, paracetamol tablets/patient consumed during the 84 day study period was 52.6 (62.0) in MOCLO, 40.0 sleep and fatigue scales of the patients on MOCLO or placebo, respectively, were statistically significant (33.6) in AMI and 73.1 (53.8) in the placebo group. ( Table II ) . DISCUSSION Beneficial changes also occurred in all dimensions of NHP with all treatments, except in mobility and in To our knowledge, this is the first randomized clinical trial assessing the efficacy and tolerability of a social life (Table III ) . The sleep and energy indices especially were improved more by AMI than by the selective and reversible MAO A inhibitor, MOCLO, in the treatment of FM. two other treatments. In within-group comparisons, AMI improved sleep, energy, pain and emotion dimenWe were unable to prove that MOCLO 450-600 mg/day is helpful in the management of FM sions statistically significantly. On the other hand, only pain or sleep dimensions reached statistically significant patients. When regarding that MOCLO elevates the concentrations of serotonin, noradrenaline, dopamine improvements in MOCLO or placebo groups, respectively ( Table III ) .
and adrenaline, and decreases their metabolites in the brain [27] , and that the central nervous system of FM AMI also improved most the changes in the dimensions of Sheehan's disability index as shown in patients appears to suffer from a deficit of these monoamines [18], the result was unexpected. Table III . In within-group comparisons, the improvements of all dimensions were statistically significant
The trend in the principal outcomes of the patients on MOCLO, however, was more favourable than that only in the AMI treatment group, although MOCLO also improved the areas of social life and family of the cases treated with placebo, although the differences did not reach statistical significance. relationships ( Table III ) .
However, when considering the individual outcomes, the patients on MOCLO improved statistically sig-
Adverse events
The percentage of patients with at least one adverse nificantly with respect to pain during the treatment period. Also, the statistically significant less use of event was 77, 74 and 80 in the MOCLO, AMI and placebo treatment groups, respectively. The corresescape paracetamol by the patients on both active drug arms than by the cases in the placebo group supports ponding figures of those adverse events, whose causal relation with the drug used by the attending physician the view that MOCLO is also effective in pain modulation in FM. The improvement in GH VAS of the was judged as possible or probable, were 58, 43 and 53%. The differences were not statistically significant.
MOCLO-treated patients most probably is also a reflection of pain reduction. The majority of discontinuations took place during the first month of the trial ( Fig. 1) . The discontinuations It is also of interest that the specific serotonin re-uptake inhibitors fluoxetin [24] and citalopram [25] have been due to adverse events did not differ statistically significantly between the treatment arms ( Fig. 1) .
proven to be failures in the treatment of FM, although Goldenberg et al.
[26 ] obtained a positive result with The most typical adverse events with at least a possible causal relationship to medication were headfluoxetine in a cross-over study of 19 FM patients. Further, in the latter study, the combination of fluoxetine ache and difficulties in falling asleep with MOCLO, dry mouth and fatigue with AMI, and fatigue and with AMI was even more beneficial than the drugs individually. The result is confusing when considering headache with placebo-treated patients. Four adverse events were judged as serious. Three of them were prethat fluoxetine has been shown to be ineffective in diabetic neuropathic pain [35] , in contrast to tricyclic scheduled operations. Additionally, one woman using AMI was hospitalized for 2 days due to a vasovagal antidepressants [35] and even other serotonin re-uptake inhibitors, citalopram [36 ] and paroxetine an increased energy level in patients on AMI. The present study also confirmed that AMI treatment in [37] .
small doses not only decreases the symptoms, but also The conflicting results may be explained by the improves the quality of life as well as perceived disabilpatient selection. The pathogenesis and chronicity of ity in patients suffering from FM. Further, the benefits FM, as it is diagnosed today [3] , most probably relate of AMI appeared early, and remained and even to various causes [2] . Further, the patients may include increased throughout the 3 month study period. individuals with different pain processing mechanisms, However, one should remember that the long-term as shown by Sö rensen et al. [38] in their placebobenefits of tricyclic antidepressants in FM remain to controlled cross-over study with morphine, ketamine be shown. and lidocaine. Moreover, we know little about the Further, AMI was shown to be superior to the distribution of serotonin, the density and distribution selective, reversible MAO A inhibitor, MOCLO, in of different types of serotonin receptors [39] , as well our patients free from major psychiatric disorders. It as the affinity of the transmitter for different types of is of practical interest, however, that MOCLO also receptors within the central nervous system, which all imposed beneficial effects on pain. Since patients influence the effects of individual drugs. In fact, Hrycaj suffering from clinically significant psychiatric diset al. [40] recently reported in a placebo-controlled orders were excluded from the present study, the study that a proportion of FM patients also respond usefulness of MOCLO in depressive FM patients to a specific serotonin receptor type-3 antagonist, onddeserves to be addressed further in controlled studies. ansetron. Further, depressive features are common in
According to the present criteria [3] , the palpation FM and the interaction of antidepressants on a of tender points is the cornerstone of clinical FM patients' psychic profile cannot be overruled when diagnosis. Although the number of tender points in considering the conflicting results of various drug the present study decreased statistically highly signifistudies. Additionally, to our knowledge, no drug trial cantly in all treatment arms, the changes were of little so far has addressed the effects of the drugs on other clinical value. The finding is in accordance with earlier plausible mechanisms for pain modulation, such as the drug trial reports, which found neither any correlation elevated levels of substance P in cerebrospinal fluid between the number of tender points and myalgic score [41-43], metabolism of other neurotransmitters or nor decreased pain [19, 21, 26 ] . Very recently, a group disturbances in hypothalamic-pituitary axis functions from The Netherlands also reported no correlation [11] [12] [13] [14] [15] [16] .
between the mean tender point score and self-reported Both AMI and MOCLO were well tolerated in the pain in FM [46 ] . On the other hand, the tender point doses used in the present study, as shown in the count both in FM [4] and in rheumatoid arthritis [47] comparable physicians' global clinical impressions in has been reported to correlate with general distress of tolerability with placebo as well as in the paucity of the patients. Therefore, the existing evidence supports drop-outs due to adverse reactions. The most typical the view that tender points and self-reported pain may adverse reactions were predictable. Although MOCLO represent different aspects of pain response in FM was dosed early during the day, difficulty in falling [46 ] . Further, the number of palpable tender points asleep was a major adverse reaction to the drug. In cannot be used as a measure of FM severity or a accordance with the finding, MOCLO also managed response criterion in clinical trials. poorly with respect to sleep quality and quantity. In
The present study confirmed that even the best fact, the alpha wave intrusion pattern during the nonavailable symptomatic drugs in FM, the small-dose REM deep-sleep phase has been proposed as a pathotricyclic antidepressants, only modestly improve the genetic factor contributing to FM [44] , although treatsymptoms, functional capacity and quality of life of ments with cyclobenzaprine [45] or AMI [21] did not non-depressed FM patients. MOCLO also decreased have any effect on this pattern in formally conducted pain, but its effects were invalidated by its negative drug trials. Nevertheless, we suggest that sleeping effects on sleep quality. When taken together, MOCLO problems contributed to the modest improvements in may be useful in patients suffering from chronic pain, fatigue VAS and NHP energy dimension in the patients but not in FM where sleeping problems occupy a very on MOCLO. Therefore, we suggest that the beneficial central position. Since both peripheral and central effects of MOCLO on pain were invalidated by its abnormalities have been suggested to be involved in negative effects on sleep quality and quantity in this the pathogenesis of FM, the mechanisms of the benefistudy.
cial effects of AMI as well as MOCLO remain to AMI has a wide range of pharmacological actions, be elucidated. However, when adding that chlorincluding inhibition of serotonin and norepinephrine methazone, a peripherally acting muscle relaxant, was re-uptake, blockade of alpha-adrenergic receptors, and proved to be ineffective in the treatment of FM [48], antagonism of muscarine, cholinergic and histaminic the findings of the majority of studies support the receptors. Its sedative and anticholinergic actions importance of central rather than peripheral mechanappear almost immediately, while the effects on pain isms behind these actions. and sleep modification are variable and delayed [23] . A In accordance with earlier studies [20, 21] , in our study AMI had an especially beneficial effect on sleep and
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